A pooled analysis of on-the-road highway driving studies in actual traffic measuring standard deviation of lateral position (i.e., “weaving”) while driving at a blood alcohol concentration of 0.5 g/L by unknown
ORIGINAL INVESTIGATION
A pooled analysis of on-the-road highway driving studies in actual
traffic measuring standard deviation of lateral position
(i.e., “weaving”) while driving at a blood alcohol concentration
of 0.5 g/L
S. Jongen1 & A. Vermeeren1 & N. N. J. J. M. van der Sluiszen1 & M. B. Schumacher2 &
E. L. Theunissen1 & K. P. C. Kuypers1 & E. F. P. M. Vuurman1 & J. G. Ramaekers1
Received: 12 August 2016 /Accepted: 20 December 2016 /Published online: 9 January 2017
# The Author(s) 2017. This article is published with open access at Springerlink.com
Abstract
Introduction The on-the-road highway driving test is general-
ly regarded as a gold standard for assessing drug-induced
driving impairment. The primary outcomemeasure is the stan-
dard deviation of lateral position (SDLP), a measure of road
tracking error or Bweaving^. The test has been calibrated for
incremental doses of alcohol almost 30 years ago in order to
define the impact of drug-induced impairment in terms of
blood alcohol concentration (BAC) equivalents. Drug-
induced changes in SDLP exceeding 2.4 cm have been eval-
uated as clinically relevant ever since. The present analysis
was conducted to assess the robustness of the alcohol effect
in a range of on-the-road driving studies which have been
conducted since the initial alcohol calibration study.
Methods The present study pooled data of 182 participants
from nine placebo-controlled crossover studies who per-
formed the highway driving test, while their BAC was at or
just below the legal limit for drivers (i.e., 0.5 g/L).
Results Overall, mean SDLP increased with 2.5 cm (95% CI
2.0–2.9 cm). Equivalence testing showed that the clinical rel-
evance criterion value of 2.4 cm fell well within the 95% CI in
each individual study. Gender did not affect alcohol-induced
changes in SDLP.
Discussion These results demonstrate the robustness and va-
lidity of the clinical relevance criterion for SDLP as measured
during on-the-road driving.
Keywords Alcohol . On-the-road driving . Standard
deviation of lateral position . Clinical relevance
Introduction
Evaluation of medicinal drug effects on the ability to operate a
motor vehicle is strongly recommended to inform both users
and prescribers (Food Drug Administration 2015; Kay and
Logan 2011). The highway driving test in actual traffic is
generally considered as an experimental gold standard to as-
sess drug-induced driving impairment. The primary outcome
measure of the driving test is standard deviation of lateral
position (SDLP) (O’Hanlon 1984). This standardized driving
test has been applied in over 75 studies and demonstrated
sensitivity to the impairing effects of several central nervous
system (CNS) drugs (Brookhuis et al. 1990; Ramaekers 1998,
2003; Theunissen et al. 2014; Vermeeren 2004; Vermeeren
et al. 2009; Verster et al. 2004).
A common approach to determine clinical relevance of drug-
induced impairment is to compare their effects to that of a bench-
mark drug known to jeopardize traffic safety, such as alcohol
(Walsh et al. 2008). Alcohol has been shown to exponentially
increase crash risk with increasing blood alcohol concentrations
(BAC) (Borkenstein 1974; Krüger et al. 1990), and legal per se
limits for driving under the influence of alcohol have been im-
plemented worldwide (Brookhuis et al. 2003). SDLP was one of
the first standardized driving measures calibrated for incremental
doses of alcohol (Louwerens et al. 1987). The results enabled
researchers in subsequent studies to interpret the magnitude of
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drug-induced impairment in terms of BAC equivalents. In the
original alcohol calibration study, participants conducted the
driving test during five alcohol conditions with a mean BAC of
0, 0.3, 0.6, 0.9, and 1.2 g/L. The driving test was conducted on a
25-km closed course in which the participants had to maintain a
constant speed of 90 km/h and a steady lateral position. Alcohol
produced an exponential rise in SDLP with increasing BACs.
Curve fitting was subsequently applied to define changes in
SDLP as a function of BAC (Fig. 2). Increments in SDLP of
2.4, 4.2, and 5.1 cm were defined as clinically relevant cutoff
points representing BACs of 0.5, 0.8, and 1.0 g/L, respectively
(Verster and Ramaekers 2009).
In subsequent studies, the same driving test was used on a
100-km primary highway with a constant speed of 95 km/h. In
these studies, the cut-off value of 2.4 cm was used as a criterion
level to define clinically relevant driving impairment of drugs
other than alcohol, as a BAC of 0.5 g/L is the legal limit for
driving under the influence of alcohol in most countries. Nine
of those studies also included alcohol treatment as a positive
control or as additional treatment to study drug-alcohol interac-
tions. In each study, an alcohol dosing regimen was used to
achieve a BAC just below the legal limit for drivers, i.e., 0.5
g/L, at the start of the driving test. The present study pooled these
datasets in order to evaluate the robustness of the alcohol-
induced changes in SDLP at a BAC of 0.5 g/L over different
settings. Changes of SDLP at a BAC of 0.5 g/L and the associ-
ated effect size observed in these nine studies were compared to
those in the original alcohol calibration study. In addition, we
performed a symmetry analysis to determine the risk of impaired
driving (Laska et al. 2012). If alcohol does not increase the risk of
impaired driving performance, the changes in SDLP (i.e., alcohol
minus placebo) will be random and symmetrical around zero. If
the symmetry analysis shows significantly more subjects with
changes above the threshold of +2.4 cm compared to the mir-
rored threshold of −2.4 cm, it can be concluded that alcohol does
increase the risk of impaired driving performance.
Methods
Studies
Table 1 shows a summary of study characteristics. Driving
data of placebo and alcohol treatments from nine studies con-
ducted byMaastricht University were included (Kuypers et al.
2006; Ramaekers et al. 2000; Ramaekers et al. 1992;
Schumacher et al. 2011; Schumacher 2014; van der Sluiszen
et al. 2016; Vermeeren and O’Hanlon 1998; Vermeeren et al.
2002a; Vermeeren et al. 2002b). Only studies which aimed to
reach a BAC of 0.5 g/L at the start of the driving test were
Table 1 Summary of nine studies included in the pooled analysis. All studies were conducted following a double-blind crossover design
Study Sample size Age range (y) Alcohol dosing Time of dosing
until start
driving test










22–44 7 constant 5.6 g, a 10 g,
and 2 adjustable doses
3 h Noon 0.45–0.37






21–45 Males 0.43 g/kg
Females 0.36 g/kg






21–45 Males 0.43 g/kg
Females 0.36 g/kg
2.15 h Noon 0.37–0.24
Kuypers et al. 2006 All 18
Male 9
Female 9






21–45 Males 3 doses
(0.23, 0.14, 0.14 g/kg)
Females 3 doses
(0.21, 0.13, 0.13 g/kg)






23–58 Males 3 doses
(0.23, 0.14, 0.14 g/kg)
Females 3 doses
(0.21, 0.13, 0.13 g/kg)
1 h Morning 0.49–0.39
Schumacher 2014 All 15
Male 6
Female 9
23–59 Males 3 doses
(0.23, 0.14, 0.14 g/kg)
Females 3 doses
(0.21, 0.13, 0.13 g/kg)
1 h Morning 0.50–0.35
BAC blood alcohol concentration
a No gender data available
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included. Two studies aimed to reach a BAC of 0.35 g/L
(Vuurman et al. 1996) and 0.8 g/L (Riedel et al. 1987), respec-
tively, and were therefore excluded. All studies were conduct-
ed according to a balanced, single or double-blind, placebo-
controlled crossover design, including one treatment condi-
tion consisting of the administration of alcohol aiming to
reach a BAC just below 0.5 g/L at the start of the driving test.
Participants
The complete dataset included 182 volunteers (92 males, 90
females) in the age range of 21 to 59 years. All participants
were healthy volunteers as determined by a medical history
questionnaire and physical examination, including electrocar-
diogram, blood hematology and chemistry, and urinalysis.
Common inclusion criteria were possession of a valid driving
license for 3 years or more, driving experience of at least
3000 km per year in the past 3 years, and a body mass index
between 19 and 29 kg m−2. Exclusion criteria were clinically
significant physical or mental disorders; drug abuse; use of
systematic medication except oral contraceptives; excessive
use of caffeine (>6 beverages containing caffeine per day),
alcohol (>21 alcohol-containing beverages per week), and
smoking (>6 cigarettes per day).
All studies were conducted at Maastricht University in ac-
cordance with the code of ethics on human experimentation
established by the Declaration of Helsinki (1964) and its sub-
sequent amendments. Studies were approved by the medical
ethics committee of Maastricht University and University
Hospital of Maastricht. Participants signed an informed con-
sent form before initiation of any study-related assessment.
Alcohol administration
All studies used weight-calibrated doses of pure alcohol
(99.8%) mixed with orange juice to achieve a BAC just under
the legal limit for drivers (i.e., 0.5 g/L) at the start of the
driving test. Alcohol-dosing regimens were either single doses
or multiple titrated doses. In four studies (Kuypers et al. 2006;
Ramaekers et al. 1992, 2000; Vermeeren and O’Hanlon
1998), gender differences were not taken into account for
calculating the dose. In five studies (Schumacher et al.
2011; Schumacher 2014; van der Sluiszen et al. 2016;
Vermeeren et al. 2002a; Vermeeren et al. 2002b), the dose
was calculated using the improved version (Watson 1981) of
theWidmark formula (Widmark 1932; Fig. 1). Breath samples
were obtained at the start and end of the driving test using a
Lion SD-3, Lion SD-400 (Lion Laboratories Ltd., Barry, UK),
or a Dräger Alcotest 6510. In all studies BACs declined over
time during driving (Table 1).
Placebo conditions
Driving performance during placebo treatment served as a
reference for determining alcohol-induced changes in SDLP.
In four studies, a placebo condition without alcohol adminis-
tration was identified (Ramaekers et al. 1992; van der Sluiszen
et al. 2016; Vermeeren and O’Hanlon 1998; Vermeeren et al.
2002a). In two studies (Ramaekers et al. 2000; Vermeeren
et al. 2002b), alcohol placebo drinks consisted of a glass of
orange juice flavored with Grand Marnier essence. In three
studies (Kuypers et al. 2006; Schumacher et al. 2011;
Schumacher 2014), a small amount (3 ml) of alcohol floating
on the surface of a glass of orange juice was used to pretend
that the beverage contained alcohol.
Highway driving test
In the standardized on-the-road highway driving test
(O’Hanlon 1984), the participant operates a specially instru-
mented vehicle over a 100-km primary highway circuit in ac-
tual traffic, accompanied by a licensed driving instructor hav-
ing access to dual controls. The task of the participant is to
maintain a constant speed of 95 km/h and a steady lateral po-
sition between the delineated boundaries of the right traffic
lane. The vehicle speed and lateral position are recorded con-
tinuously. These signals are digitized at a rate of 4 Hz and
edited offline to remove data recorded during overtaking ma-
neuvers or disturbances caused by roadway or traffic situations.
The remaining data are then used to calculate mean values and
Fig. 1 Formulas for calculating
blood alcohol concentrations
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standard deviation of lateral position (SDLP, in centimeter) for
each successive 5-km segment and, as the square root of pooled
variance over all segments, for the test as a whole. SDLP is the
primary performance parameter, which is an index of road-
tracking error or Bweaving^ (Fig. 2). Several different cars
and circuits in Belgium and the Netherlands have been used
over the years.
Statistical analysis
The overall alcohol effect was analyzed using a 2 × 2 × 9 gen-
eral linear model (GLM) repeated measures analysis with al-
cohol treatment (placebo and alcohol) as within-subject factor
and gender and study as between-subject factors. In addition,
alcohol and gender effects were assessed for each study sep-
arately by using 2 × 2 GLM repeated measures. Equivalence
testing was applied to assess whether the predefined alcohol
criterion of 2.4 cm fell within the 95% confidence interval (CI)
of the mean difference scores (i.e.,ΔSDLP) of the individual
studies.
To determine the magnitude of the alcohol effect on SDLP,
effect sizes (ES) for repeated measures designs were calculat-
ed for all studies combined and for each study separately
(ES = tc[2(1-r)/n]
1/2) (Dunlap et al. 1996). An ES between
0.00 and 0.19 was considered small, between 0.20 and 0.69
moderate, and higher than 0.70 large (Lakens 2013).
To detect an asymmetry in the distribution of the individual
difference scores between SDLP after alcohol and placebo, a
McNemar test was used (Laska et al. 2012). This test exam-
ines the difference in proportions of impaired and improved
drivers following alcohol using a generalized sign test over the
relevant threshold of 2.4 cm, which is the predefined criterion
used for a mean increase of SDLP. Symmetry implies that the
probability of impairment over placebo is the same as the
probability of improvement. Rejecting the null hypothesis
implies that the two probabilities are unequal, indicating that




Gender data could not be retrieved in two studies (Ramaekers
et al. 1992, 2000). These datasets were included in the overall
effect of alcohol on SDLP, but were removed from gender
analyses.
Mean changes in SDLP scores
Table 2 shows overall and individual study means of SDLP
scores in placebo and alcohol conditions and their correspond-
ing mean (95% CI) ΔSDLP. Repeated measures analysis of
variance showed that the overall mean increase (95% CI) in
SDLPwas 2.5 cm (2.0–2.9) (F1, 181 = 132.78, p < 0.001) in the
alcohol condition compared to placebo. The overall effect size
was moderate 0.54 (range 0.45–0.73). Overall, alcohol-
induced changes in SDLP did not significantly differ between
studies (F6,134 = 1.30, p = 0.263) and gender (F1,134 = 0.14,
p = 0.708).
Alcohol-induced increments in SDLP ranged from +1.9 to
+3.6 cm across all driving studies. Equivalence testing
showed that in each individual study, the criterion value of
2.4 cm fell well within the 95% CI (Fig. 3). Overall, the mean
increase of SDLP in males (95% CI) was 2.4 cm (1.7–3.1)
with an effect size of 0.51 (range 0.37–0.92) and in females
2.5 cm (2.0–3.1) with an effect size of 0.51 (range 0.40–1.06).
Effect sizes of individual studies are reported in Table 2.
Fig. 2 Standardized highway driving test. a Participants drive a specially
instrumented vehicle for about 1 h over a 100 km primary highway
circuit, accompanied by a licensed driving instructor having access to
dual controls. The participants’ task is to drive with a steady lateral
position between the delineated boundaries of the slower right traffic
lane, while maintaining a constant speed of 95 km/h. b The standard
deviation of lateral position (SDLP in centimeter) is an index of road
tracking error or Bweaving^. c The relationship between blood alcohol
concentration and SDLP as obtained by Louwerens et al. (1987)
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Proportion of impaired and improved drivers
Symmetry analysis of SDLP changes in individual
drivers confirmed that alcohol significantly impairs driv-
ing performance (McNemar test 72.90, p < 0.001).
Overall, 47.3% (86 out of 182 participants) of the drivers
showed increments in SDLP that exceeded the criterion
level of 2.4 cm. In contrast, only 2.2% (i.e., 4 partici-
pants) of the drivers showed improvement following al-
cohol that exceeded the mirrored criterion value of
−2.4 cm. In males, the distribution of individual drivers
showing driving impairment or improvement beyond the
criterion value was 42.7% (i.e., 32 participants) and 2.7%
(i.e., 2 participants) (McNemar test 24.74, p < 0.001). In
females, 52.1% (i.e., 38 participants) of the drivers
showed alcohol-induced impairment, whereas none im-
proved (McNemar test 36.03, p < 0.001) (Fig. 4). It
should be noted that gender data deviates from the total
regarding proportion of impaired and improved drivers,
because no gender data were available for the 34
participants.
Table 2 Overall mean (SD) score of standard deviation of lateral posi-
tion (SDLP) after placebo (PBO) and alcohol (ALC), mean (95% CI)
change scores (Δ SDLP), repeated measure analyses of variance,
Dunlap’s effect sizes and proportion improved vs. impaired driver, and
for each study and gender separately
Study SDLP PBO (SD) SDLPALC (SD) ΔSDLP (95% CI) F p Dunlap’s ES Improved/
impaired
Ramaekers et al. 1992 Alla 20.2 (4.0) 23.2 (4.6) 3.0 (0.9–5.2) 8.9 <0.01 0.69 00/08
Vermeeren and O’Hanlon 1998 All 21.9 (5.7) 25.5 (7.3) 3.6 (1.9–5.3) 19.0 <0.001 0.52 02/15
Male 22.2 (5.6) 25.3 (7.1) 3.1 (−0.3–6.4) – NS 0.47 02/06
Female 21.6 (6.1) 25.8 (7.8) 4.1 (2.6–5.7) 34.5 <0.001 0.42 00/09
Ramaekers et al. 2000 Alla 22.3 (4.8) 24.4 (3.4) 2.0 (0.5–3.5) 8.3 <0.05 0.45 02/08
Vermeeren et al. 2002a All 20.0 (3.6) 22.3 (3.9) 2.3 (1.5–3.1) 37.3 <0.001 0.59 00/10
Male 19.5 (4.4) 21.1 (4.4) 1.6 (0.4–2.9) 8.9 <0.05 0.37 00/03
Female 20.5 (2.8) 23.5 (3.3) 3.0 (1.9–4.0) 39.5 <0.001 0.93 00/07
Vermeeren et al. 2002b All 17.7 (3.0) 19.4 (3.7) 1.7 (0.7–2.6) 12.9 <0.01 0.49 00/07
Male 18.0 (3.2) 20.3 (4.2) 2.3 (0.3–4.2) 6.4 <0.05 0.58 00/06
Female 17.4 (2.7) 18.5 (2.8) 1.1 (0.6–1.5) 24.3 <0.001 0.40 00/01
Kuypers et al. 2006 All 20.6 (3.9) 23.5 (4.0) 2.9 (1.2–4.5) 13.5 <0.01 0.73 00/09
Male 20.2 (3.9) 23.8 (3.8) 3.6 (1.1–6.0) 11.2 <0.05 0.92 00/05
Female 21.1 (4.0) 23.3 (4.4) 2.2 (−0.5–4.8) – NS 0.51 00/04
van der Sluiszen et al. 2016 All 17.0 (2.6) 19.4 (3.4) 2.5 (1.7–3.2) 46.7 <0.001 0.72 00/12
Male 17.2 (2.2) 18.9 (2.8) 1.7 (0.6–2.8) 11.5 <0.01 0.63 00/03
Female 16.8 (3.1) 20.0 (4.0) 3.2 (2.2–4.1) 50.3 <0.001 0.79 00/09
Schumacher et al. 2011 All 18.3 (4.1) 20.7 (3.3) 2.4 (1.2–3.6) 18.4 <0.05 0.61 00/10
Male 18.5 (4.5) 20.5 (3.6) 2.0 (0.5–3.6) 8.1 <0.05 0.47 00/06
Female 17.9 (3.4) 21.3 (2.7) 3.4 (1.1–5.8) 16.4 <0.05 1.06 00/04
Schumacher 2014 All 19.7 (3.3) 21.5 (3.2) 1.9 (0.6–3.2) 10.1 <0.01 0.58 00/07
Male 19.2 (5.2) 22.0 (3.9) 2.8 (0.3–5.2) 8.0 <0.05 0.52 00/03
Female 20.0 (1.6) 21.3 (2.9) 1.3 (−0.4–3.0) – NS 0.48 00/04
Total All 182 19.6 (4.3) 22.1 (4.8) 2.5 (2.0–2.9) 132.8 <0.001 0.54 04/86
Male 75b 19.2 (4.3) 21.6 (4.8) 2.4 (1.7–3.1) 42.8 <0.001 0.51 02/32b
Female 73b 19.2 (4.0) 21.7 (5.0) 2.5 (2.0–3.1) 93.1 <0.001 0.51 00/38b
BAC blood alcohol concentration, PBO placebo, ALC alcohol, ES effect size, NS not significant
a No gender data available
b Gender data deviates from total, because no gender data were available of 34 participants
Fig. 3 Overall mean change of standard deviation of lateral position (Δ
SDLP, in centimeter) with 95% confidence interval (CI) and mean
changes of SDLP with 95% CI of each individual study after alcohol
reaching a blood alcohol concentration (BAC) of 0.5 g/L. The vertical
black line is the clinically relevant cutoff point of 2.4 cm, as defined by
Louwerens et al. (1987). Study 1: Ramaekers et al. 1992, Study 2:
Vermeeren and O’Hanlon 1998, Study 3: Ramaekers et al. 2000, Study
4: Vermeeren et al. 2002a, Study 5: Vermeeren et al. 2002b, Study 6:
Kuypers et al. 2006, Study 7: van der Sluiszen et al. 2016, Study 8:
Schumacher et al. 2011, Study 9: Schumacher 2014
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Discussion
The aim of the present paper was to evaluate the robustness of
an SDLP increase of 2.4 cm during highway driving at a BAC
of 0.5 g/L, as determined by an alcohol calibration study al-
most 30 years ago (Louwerens et al. 1987). For this purpose,
data from 182 participants of nine placebo-controlled studies
using the same driving test and comparable methods were
pooled and analyzed. It was found that alcohol at a BAC of
0.5 g/L led to a mean ΔSDLP of 2.5 cm, and that alcohol-
induced changes in SDLP did not significantly differ between
individual driving studies. In addition, it was shown that the
previously defined alcohol criterion value of 2.4 cm fell within
the 95% CI of the meanΔSDLP following alcohol in all nine
studies that were included in the current analysis. The overall
mean ΔSDLP of 2.5 cm following at a BAC of 0.5 g/L ap-
proaches the predefined cutoff value of 2.4 cm found by
Louwerens et al. (1987) at the same BAC. This supports the
notion that this value can and should be used as a cutoff point
for determining clinically relevance of driving impairment
observed for drugs other than alcohol when screened in the
standardized highway driving test.
The present analysis did not reveal any difference between
the magnitude of alcohol-induced impairment in males and
females. In contrast, Louwerens et al. (1987) reported higher
alcohol induced changes in SDLP in females as compared to
males. Two explanations may be offered for this discrepancy.
First, increased sensitivity for alcohol in females only became
apparent at a BAC of 0.6 g/L and higher in the study by
Louwerens et al. (1987). In the present studies, however,
BAC values never exceeded a BAC of 0.5 g/L and thus may
not have been sufficient to evoke a gender difference. Second,
alcohol dosing in the study by Louwerens et al. (1987) was



























Fig. 4 Individual and mean
(horizontal lines) alcohol-placebo
changes in driving performance
as measured by the standard
deviation of lateral position
(SDLP). Change scores for each
individual study are shown
separately for males (squares) and
females (triangles) and for
individuals for whom gender data
was missing (circles). Dotted
lines show thresholds for
impaired (changes above 2.4 cm)
and improved driving (changes
below −2.4 cm). Study 1:
Ramaekers et al. 1992, Study 2:
Vermeeren and O’Hanlon 1998,
Study 3: Ramaekers et al. 2000,
Study 4: Vermeeren et al. 2002a,
Study 5: Vermeeren et al. 2002b,
Study 6: Kuypers et al. 2006,
Study 7: van der Sluiszen et al.
2016, Study 8: Schumacher et al.
2011, Study 9: Schumacher 2014
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volume distribution (i.e., lean body mass) (Goist and Sutker
1985; Watson et al. 1980). This actually resulted in higher
BACs in female participants compared to males receiving
the same amount of alcohol/kilogram body weight. In con-
trast, more than half of the studies in the current analysis took
the difference in volume distribution of alcohol between gen-
der into account, leading to equal BACs between males and
females. The present demonstration of the absence of gender
specific sensitivity for alcohol effects on SDLP is also in line
with a recent review of alcohol impaired driving. Martin et al.
(2013) reviewed the scientific literature on alcohol-induced
impairment as reported in neurocognitive, simulator, closed-
course, and on-road driving studies and concluded that gender
had little impact on alcohol-induced impairment at BAC
levels below 1.0 g/L. Together, these data suggest that an
SDLP criterion value of 2.5 cm can be reliably applied across
gender to define alcohol-induced impairment at a BAC of
0.5 g/L.
Symmetry analysis confirmed the finding that alcohol sig-
nificantly increases mean SDLP. It was expected that the num-
ber of individual drivers whose ΔSDLP exceeded the criteri-
on value of 2.4 cm exceed the number of drivers whose driv-
ing actually improved bymore than −2.4 cm. In the absence of
any alcohol effect, the distribution of ΔSDLP for individual
drivers above and below the criterion value of 2.4 and −2.4 cm
was expected to be the same assuming a normal distribution of
random changes. Alcohol at a BAC of 0.5 g/L was associated
with 47.3% of individual drivers whoseΔSDLP exceeded the
criterion value of 2.4 cm. In contrast, only a small proportion
(2.2%) of drivers demonstrated a ΔSDLP that fell below the
mirrored criterion of −2.4 cm. However, the cutoff point for
individual performance changes in SDLP has not yet been
formally validated and should therefore deserve further
research.
One point that should be noted is that observed BACs
during the driving test decreased over time.Mean BAC during
driving (i.e., average of BAC at onset and end of the driving
test) was therefore somewhat lower than the targeted BAC of
0.5 g/L at the onset of the driving test. This means that the
clinically relevant cutoff point previously used in clinical trials
was rather conservative and might actually be higher. Due to
legal restrictions, it is unwarranted to reach a BAC higher than
0.5 g/L at the start of the driving test. Still, the current estima-
tion ofΔSDLP at a BAC of 0.5 g/L provides a well validated
and close estimate of the minimal degree of drug-induced
driving impairment in the standardized highway driving test
that can be associated with actual crash risk.
In conclusion, the present study showed and replicated a
robust overall mean ΔSDLP of 2.5 cm during highway driv-
ing at a BAC of 0.5 g/L. These data indicate that ΔSDLP of
2.5 cm can be reliably used to determine clinical relevance of
drug-induced driving impairment in the standardized highway
driving test.
Compliance with ethical standards All studies were conducted in
accordance with the code of ethics on human experimentation established
by the Declaration of Helsinki (1964) and its subsequent amendments.
Studies were approved by the medical ethics committee of Maastricht
University and University Hospital of Maastricht. Participants signed an
informed consent form before initiation of any study-related assessment.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
Borkenstein RF, Crowther RF, Shumate RP (1974) The role of the drink-
ing driver in traffic accidents (The Grand Rapids Study).
Blutalkohol 11(Suppl):1–131
Brookhuis KA, De Waard D, Fairclough SH (2003) Criteria for driver
impairment. Ergonomics 46(5):433–445. doi:10.1080/001401302
/1000039556
Brookhuis KA, Volkerts ER, O’Hanlon JF (1990) Repeated dose effects
of lormetazepam and flurazepam upon driving performance. Eur J
Clin Pharmacol 39(1):83–87
Dunlap WP, Cortina JM, Vaslow JB, Burke MJ (1996) Meta-analysis of
experiments with matched groups or repeated measures designs.
Psychol Methods 1(2):170–177. doi:10.1037/1082-989X.1.2.170
Food Drug Administration (2015). FDA guidance for industry: evaluat-
ing drug effects on the ability to operate a motor vehicle guidance
for industry (Draft Guidance), available at: http://www.fda.
gov/Drugs/GuidanceComplianceRegulatoryInformation/
Guidances/UCM430374
Goist KC, Sutker PB (1985) Acute alcohol intoxication and body com-
position in women and men. Pharmacol Biochem Behav 22(5):811–
814
Kay G, Logan B (2011) Drugged driving expert panel report: a consensus
protocol for assessing the potential of drugs to impair driving. (DOT
HS 811 438). National Highway Traffic Safety Administation,
Washington, DC
Krüger, H. P., Kohnen, R., Diehl, M., and Hüppe, A. (1990).
Auswirkungen geringer Alkoholmengen auf Fahrverhalten und
Verkehrssicherheit
Kuypers KP, Samyn N, Ramaekers JG (2006) MDMA and alcohol ef-
fects, combined and alone, on objective and subjective measures of
actual driving performance and psychomotor function.
Psychopharmacology 187(4):467–475. doi:10.1007/s00213-006-
0434-z
Lakens D (2013) Calculating and reporting effect sizes to facilitate cu-
mulative science: a practical primer for t-tests and ANOVAs. Front
Psychol 4:863. doi:10.3389/fpsyg.2013.00863
Laska E, Meisner M, Wanderling J (2012) A maximally selected test of
symmetry about zero. Stat Med 31(26):3178–3191. doi:10.1002
/sim.5384
Louwerens J, Gloerich A, de Vries G, Brookhuis K, O’Hanlon J (1987)
The relationship between drivers’ blood alcohol concentration
(BAC) and actual driving performance during high speed travel.
In: Noordzij PC, Roszbach R (eds) Alcohol drugs traffic safety.
Amsterdam, T86 Elsevier, pp 183–186
Martin TL, Solbeck PAM, Mayers DJ, Langille RM, Buczek Y, Pelletier
MR (2013) A review of alcohol-impaired driving: the role of blood
alcohol concentration and complexity of the driving task. J Forensic
Sci 58(5):1238–1250. doi:10.1111/1556-4029.12227
Psychopharmacology (2017) 234:837–844 843
O’Hanlon JF (1984) Driving performance under the influence of drugs:
rationale for, and application of, a new test. Br J Clin Pharmacol
18(Suppl 1):121S–129S
Ramaekers JG (1998) Behavioural toxicity of medicinal drugs. Drug Saf
18(3):189–208
Ramaekers JG (2003) Antidepressants and driver impairment: empirical
evidence from a standard on-the-road test. The Journal of Clinical
Psychiatry 64(1):20–29
Ramaekers JG, Robbe HW, O’Hanlon JF (2000) Marijuana, alcohol and
actual driving performance. Hum Psychopharmacol 15(7):551–558
Ramaekers JG, Uiterwijk MMC, O'hanlon JF (1992) Effects of loratadine
and cetirizine on actual driving and psychometric test performance,
and EEG during driving. Eur J Clin Pharmacol 42(4):363–369
Riedel, W. J., Schoenmakers, E. A. J. M., and O'Hanlon, J. F. (1987). The
effects of loratadine alone and in combination with alcohol on ac-
tual driving performance. Institute for Drugs, Safety and Behavior,
University of Limburg
Schumacher, M. (2014). Erfassung der Fahrsicherheit unter
psychoaktiver Medikation am Beispiel der Langzeitanwendung
von Opioiden bei chronischem Schmerz (Dissertation). Technische
Universität, Braunschweig. Retrieved from http://www.digibib.tu-
bs.de/?docid=00056091
Schumacher M, Knoche A, Vollrath M, Petzke F, Jantos R, Vuurman E,
Ramaekers J (2011) Chapter 8: effects of analgetic medication on
actual driving. Driving under the Influence of Drugs (DRUID)
Deliverable 1(2):2 Available at http://www.druid-project.
eu/Druid/EN/deliverales-list/downloads/Deliverable_1_2_2.
html?nn=613800
Theunissen EL, Kuypers KP, Vermeeren A, Vuurman EF, Ramaekers JG
(2014) Effects of medicinal drugs on fitness to drive. Handbook of
Forensic Medicine:1087–1098. doi:10.1002/9781118570654.ch60
van der Sluiszen NNJJM, Vermeeren A, Jongen S, Theunissen EL, van
Oers ACM, Van Leeuwen CJ et al (2016) On-the-road driving per-
formance after use of the antihistamines mequitazine and l-
mequitazine, alone and with alcohol. Psychopharmacology 233:1–9
Verster JC, Ramaekers JG (2009) The on-the-road driving test. In: Verster
JC, Pandi-Perumal SR, Ramaekers JG, de Gier JJ (eds) Drugs, driv-
ing and traffic safety. Birkhauser Verlag AG, Basel, Switzerland, pp
59–74
Vermeeren A (2004) Residual effects of hypnotics: epidemiology and
clinical implications. CNS Drugs 18(5):297–328
Vermeeren A, Leufkens TRM, Verster JC (2009) Effects of anxiolytics on
driving. In: Verster JC, Pandi-Perumal SR, Ramaekers JG, deGier JJ
(eds) Drugs, driving and traffic safety. Birkhauser Verlag AG, Basel,
Switzerland, pp 59–74
VermeerenA, O’Hanlon JF (1998) Fexofenadine’s effects, alone and with
alcohol, on actual driving and psychomotor performance. The
Journal of Allergy and Clinical Immunology 101(3):306–311.
doi:10.1016/S0091-6749(98)70240-4
VermeerenA, Ramaekers JG, O’Hanlon JF (2002a) Effects of emedastine
and cetirizine, alone and with alcohol, on actual driving of males and
females. J Psychopharmacol 16(1):57–64
Vermeeren A, Riedel WJ, van Boxtel MP, Darwish M, Paty I, Patat A
(2002b) Differential residual effects of zaleplon and zopiclone on
actual driving: a comparisonwith a low dose of alcohol. Sleep 25(2):
224–231
Vermeeren A, Vuurman EFPM, Leufkens TRM, Van Leeuwen CJ, Van
Oers ACM, Laska E et al (2014) Residual effects of low-dose sub-
lingual zolpidem on highway driving performance the morning after
middle-of-the-night use. Sleep 37(3):489–496. doi:10.5665
/sleep.3482
Verster JC, Veldhuijzen DS, Volkerts ER (2004) Residual effects of sleep
medication on driving ability. Sleep Med Rev 8(4):309–325
Vuurman EFPM, Muntjewerff ND, Uiterwijk MMC, Van Veggel LMA,
Crevoisier C, Haglund L et al (1996) Effects of mefloquine alone
and with alcohol on psychomotor and driving performance. Eur J
Clin Pharmacol 50(6):475–482
Walsh JM, Verstraete AG, Huestis MA, Mørland J (2008) Guidelines for
research on drugged driving. Addiction 103(8):1258–1268.
doi:10.1111/j.1360-0443.2008.02277.x
Watson PE, Watson ID, Batt RD (1980) Total body water volumes for
adult males and females estimated from simple anthropometric mea-
surements. Am J Clin Nutr 33(1):27–39
Watson P, Watson I, Batt R (1981) Prediction of blood alcohol concen-
trations in human subjects; updating the Widmark equation. Journal
of studies on alcohol and drugs 42(07):547
Widmark, E. M. P. (1932). Die theoretischen Grundlagen und die
praktische Verwendbarkeit der gerichtlich- medizinischen
Alkoholbestimmung. Urban and Schwarzenberg.
844 Psychopharmacology (2017) 234:837–844
